Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$40.46 USD
-0.71 (-1.72%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $40.46 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.46 USD
-0.71 (-1.72%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $40.46 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Zacks News
Will Tandem Diabetes Care Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Tandem Diabetes.
Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?
by Zacks Equity Research
Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings
by Zacks Equity Research
Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter
Molina Healthcare (MOH) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect lower premium revenues and decline in medical membership.
What's in the Offing for LabCorp's (LH) Earnings in Q4?
by Zacks Equity Research
With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.
What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.
The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor
5 Top-Ranked Growth Stocks for February That Have Jumped YTD
by Nalak Das
Several positive factors have strengthened investors' confidence in risky assets like equities. A few top-ranked growth stocks surged in January and still have strong upside left.
Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?
by Zacks Equity Research
Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.
What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.
Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express
by Zacks Equity Research
Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express
Moving Average Crossover Alert: Tandem Diabetes Care
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Check 4 Best Liquid Bets to Power Your Portfolio
by Zacks Equity Research
Four top-ranked liquid stocks that investors can bank on for fat returns.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.
Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Moving Average Crossover Alert: Tandem Diabetes Care
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
by Zacks Equity Research
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Diabetes Management Gains FDA Attention: 3 Stocks in Focus
by Sriparna Ghosal
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry
by Zacks Equity Research
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
6 MedTech Stocks That are Set to Beat the Market in 2020
by Trina Mukherjee
Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.